Author Affiliations: Minneapolis VA Center for Chronic Disease Outcomes Research and Department of Medicine, University of Minnesota (Dr Wilt), Minneapolis; and Department of Clinical Policy, American College of Physicians, Philadelphia, Pennsylvania (Dr Qaseem).
Type 2 diabetes mellitus (DM) is a leading cause of morbidity and mortality, affecting nearly 26 million people and costing $174 billion in the United States.1 Monotherapy with oral agents lower hemoglobin A1c (HbA1c) levels an average of 1% of total hemoglobin. Combination therapy with a second oral medication or insulin leads to an additional 1% to 2% reduction. (To convert HbA1cto a proportion of total hemoglobin, multiply by 0.01.) Most people with type 2 DM will receive more than 1 class of medication: 14% take both insulin and oral medications, and 58% take multiple oral DM medications.1
Wilt TJ, Qaseem A. Implementing High-Value, Cost-Conscious Diabetes Mellitus Care Through the Use of Low-Cost Medications and Less-Intensive Glycemic Control TargetComment on "Variation in Use of High-Cost Diabetes Mellitus Medications in the VA Healthcare System". Arch Intern Med. 2012;172(20):1610-1611. doi:10.1001/2013.jamainternmed.203